Lopez-Tarruella, Sara http://orcid.org/0000-0002-2606-9538
Escudero, M. J.
Pollan, Marina
Martín, Miguel http://orcid.org/0000-0001-9237-3231
Jara, Carlos
Bermejo, Begoña
Guerrero-Zotano, Angel
García-Saenz, José
Santaballa, Ana
Alba, Emilio
Andrés, Raquel
Martínez, Purificación
Calvo, Lourdes
Fernández, Antonio http://orcid.org/0000-0003-3897-2262
Batista, Norberto
Llombart-Cussac, Antonio
Antón, Antonio
Lahuerta, Ainhara
de la Haba, Juan
López-Vega, José Manuel
Carrasco, E.
Article History
Received: 17 May 2019
Accepted: 2 December 2019
First Online: 27 December 2019
Competing interests
: Dr. López-Tarruella has consultancy/advisory role for AstraZeneca, Novartis, Roche, Pfizer, Celgene, Pierre-Fabre, Eisai and Lilly. Dr. García-Sáenz has received consultancy/speaker fees from Novartis, Celgene, Eli Lilly, EISAI and Roche. Travel support from Novartis, Roche as well as Pfizer and his institution’s research funding from AstraZeneca. Dr. Jara has received speaker fees from Roche, Pfizer, Eisai, Novartis and Kyowa as well as travel support from Roche and Pfizer. Dr. Martínez has received consultancy/speaker fees from Leo Pharma, AstraZeneca, Pfizer, and Tesaro as well as travel support from Roche, Rovi and Boehringer Ingelheim. Dr. Martín has a consultant or advisory role with AstraZeneca, Novartis, Roche-Genentech, Pfizer, Glaxo, PharmaMar, Taiho Oncology and Lilly; he has received honoraria from Pfizer and Lilly; he has received research funding from Novartis and Roche. Dr. Guerrero has received travel support from Pfizer. Dr. Antón has consultant/advisory role for Roche and Bayern. Dr. Carrasco has received travel support from Roche and her institution has received funding from Roche, Novartis, Pfizer, BMS, Celgene, AstraZeneca and MSD. Dr. Llombart has received honoraria from Roche, Lilly, Pfizer and Novartis; he has a consultant/advisory role for Roche; he has received funding from Roche, Eisai, AstraZeneca, Lilly and Pfizer and has stock ownership from MedSIR. The rest of the authors declare no conflicts of interest.